Nmnat2 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Nmnat2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NMNAT2 (NMN Adenylyltransferase 2) is a critical enzyme in neuronal NAD+ biosynthesis that maintains axonal integrity and protects against Wallerian degeneration.
| Property | Value |
|----------|-------|
| Protein Name | NMN Adenylyltransferase 2 |
| Gene | NMNAT2 |
| UniProt ID | Q9H0M0 |
| PDB Structures | 4OQY, 5MJB |
| Molecular Weight | 46.2 kDa |
| Subcellular Localization | Cytosol, enriched in axons |
| Protein Family | NMN adenylyltransferase family |
¶ Domain Architecture:
- N-terminal Domain: Variable region involved in axonal targeting
- Adenylyltransferase Domain: Central catalytic domain (~350 aa) that binds NMN and ATP
- C-terminal Region: Regulatory region affecting protein stability
- The catalytic domain adopts a Rossmann-like fold typical of nucleotidyltransferases
- Dimerization is required for enzymatic activity
- The protein forms homodimers in solution
- Catalyzes the ATP-dependent conversion of NMN to NAD+
- Uses ATP as an adenylate donor
- Km for NMN: ~10 μM; Km for ATP: ~100 μM
- NAD+ Maintenance: Primary source of neuronal NAD+ in axons
- Axonal Energy Metabolism: NAD+ serves as essential cofactor for glycolytic and mitochondrial enzymes
- Signaling: NAD+ is substrate for sirtuins, PARPs, and CD38/157 ectoenzymes
- Axonal Protection: NMNAT2 protein levels determine whether axons survive or degenerate after injury
- NMNAT2 is a key substrate for SARM1's NADase activity
- SARM1 activation leads to rapid NMNAT2 degradation
- NAD+ depletion triggers axonal energy crisis and degeneration
- NMNAT2 levels decline after axotomy due to lack of somatic support
- Declining NMNAT2 leads to NAD+ depletion via SARM1
- The "Wallerian degeneration" phenotype (slow degeneration) is NMNAT2-dependent
- WLD^S mice overexpress NMNAT2 and show axon protection
- NAD+ levels decline in AD brain
- Impaired NMNAT2 function may contribute to synaptic loss
- NAD+ supplementation approaches are being explored
- Dopaminergic neurons require high energy output
- NMNAT2 dysfunction may contribute to axonal vulnerability
- SARM1-mediated degeneration may play a role
- Rare NMNAT2 variants cause axonal CMT2
- Affected individuals present with distal muscle weakness and sensory loss
| Compound |
Mechanism |
Status |
| NMN |
Direct NMNAT2 substrate |
Preclinical |
| Nicotinamide Riboside |
NAD+ precursor |
Clinical trials |
| Nicotinamide |
NAD+ precursor |
Approved supplements |
- Small molecule SARM1 inhibitors in development
- Goal: Prevent NMNAT2 degradation and NAD+ depletion
- Potential for treating peripheral neuropathies and traumatic nerve injury
- AAV-mediated NMNAT2 overexpression approaches
- Targeting peripheral nervous system first
Nmnat2 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Nmnat2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.